Wu A, Nashan B, Messner U, Schmidt H H, Guenther H H, Niesert S, Pichmayr R
Klinik fuer Abdominal- und Transplantationschirurgie, Medizinische Hochschule Hannover, Germany.
Clin Transplant. 1998 Oct;12(5):454-64.
To evaluate course and outcome of pregnancies in liver transplanted patients and to provide a brief summary on the development of these children, 22 pregnancies and 23 children (1 month-99 months old) of 16 patients who had been liver transplanted at our institution (mean interval from transplantation to pregnancy 43.1 months) were reviewed. Standard immunosuppressive regimen during pregnancy consisted of cyclosporine A (CyA), tacrolimus (FK), azathioprine (Aza) and/or a low-dose steroid therapy. CyA and FK whole blood trough levels were monitored on a routinely basis to keep therapeutic range (CyA 80-150 ng/mL; FK 4-8 ng/mL). No patient had a graft loss and there were no lethal complications. Beside de novo hypertension (n = 3) and preeclampsia (n = 3) problems during pregnancy included one steroid-sensitive rejection at 36 wk gestation, one case of tacrolimus toxicity at 24 wk with complete reconstitution, and one case of de novo choledocholithiasis with recurrent cholangitis. Three cases of infections occurred. In total, 23 children, including one set of twins, were born. Terms of gestation (mean = 38.1 wk, +/- 2.2 SD), deliveries (spontaneous n = 13, cesarean section n = 7, forceps n = 1, vacuum extraction (VE) n = 1) and birth weights (2876 g, +/- 589.3 SD) were typical. Three pregnancies were preterm, one being a twin pregnancy. Neither congenital malformations nor unusual infections were seen in the children. Postnatal follow-up revealed appropriate physical growth to date. Psychological development seems to be adequate. Our data indicate that successful pregnancies after liver transplantation (LTX) under careful management by transplant specialists, obstetricians and perinatalogists have a good outcome. So far, neither pre- nor postnatal child development appear to be influenced by maternal immunosuppressive therapy during pregnancy.
为评估肝移植患者的妊娠过程及结局,并简要总结这些儿童的发育情况,我们回顾了在我院接受肝移植的16例患者的22次妊娠及23名儿童(年龄1个月至99个月)(从移植到妊娠的平均间隔时间为43.1个月)。孕期的标准免疫抑制方案包括环孢素A(CyA)、他克莫司(FK)、硫唑嘌呤(Aza)和/或低剂量类固醇疗法。常规监测CyA和FK的全血谷浓度以维持治疗范围(CyA 80 - 150 ng/mL;FK 4 - 8 ng/mL)。无患者发生移植物丢失,也无致命并发症。除了新发高血压(n = 3)和先兆子痫(n = 3),孕期问题还包括1例妊娠36周时的类固醇敏感型排斥反应、1例妊娠24周时他克莫司毒性反应且完全恢复、1例新发胆总管结石伴复发性胆管炎。发生了3例感染。总共出生了23名儿童,包括1对双胞胎。妊娠期限(平均 = 38.1周,±2.2标准差)、分娩方式(自然分娩n = 13、剖宫产n = 7、产钳助产n = 1、真空吸引术(VE)n = 1)和出生体重(2876 g,±589.3标准差)均属正常。3例妊娠为早产,其中1例为双胎妊娠。儿童中未见先天性畸形或异常感染。产后随访显示至今身体生长正常。心理发育似乎也正常。我们的数据表明,在移植专家、产科医生和围产医学专家的精心管理下,肝移植(LTX)后成功妊娠结局良好。到目前为止,孕期母亲的免疫抑制治疗似乎未对胎儿的产前及产后发育产生影响。